Crossmark

Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy

Crossref DOI link: https://doi.org/10.1186/s12916-016-0609-3

Published Online: 2016-04-07

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Honeyborne, Isobella

McHugh, Timothy D.

Kuittinen, Iitu

Cichonska, Anna

Evangelopoulos, Dimitrios

Ronacher, Katharina

van Helden, Paul D.

Gillespie, Stephen H.

Fernandez-Reyes, Delmiro

Walzl, Gerhard

Rousu, Juho

Butcher, Philip D.

Waddell, Simon J.
Funding

Funding for this research was provided by:

European Union Innovative Medicines Initiative (115337)

Wellcome Trust

Medical Research Council (G0601466)

European Metrology Research Programme

GlaxoSmithKline Action TB Initiative

Medical Research Council (SA)